🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Allay Therapeutics secures $57.5M in Series D funding and venture debt to further develop ATX101 and its pain management platform for post-surgical pain. More Info: pryzm.ozmosi.com/product/33592 $XBI $IBB $XPH $PPH

$ARTL ART26.12, Artelo's Fatty Acid Binding Protein 5 Inhibitor, shows positive results in an osteoarthritis pain study compared to naproxen. More Info: pryzm.ozmosi.com/product/25457 $XBI $IBB $XPH $PPH

Health Canada approves RADIESSE® from Merz Aesthetics® for treating moderate wrinkles in the décolleté area. More Info: pryzm.ozmosi.com/product/20086 $XBI $IBB $XPH $PPH

64Cu-SARTATE shows high efficacy in tumor detection for NET patients compared to standard imaging. Phase III plans in progress for DISCO study. More Info: pryzm.ozmosi.com/product/27167 $XBI $IBB $XPH $PPH

Key points from Mabwell's 9MW2821 presented at 2025 ASCO will be discussed in the oral presentation. More Info: pryzm.ozmosi.com/product/25004 $XBI $IBB $XPH $PPH

First patient treated in Phase 1 trial by ImPact Biotech using Padeliporfin VTP for unresectable PDAC. More Info: pryzm.ozmosi.com/product/6609 $XBI $IBB $XPH $PPH

$TSX:LIRC Lithium Royalty Corp. congratulates Power Metals on world-scale cesium discovery, offering potential near-term revenue for LRC. More Info: pryzm.ozmosi.com/product/3477 $XBI $IBB $XPH $PPH

Long-term data on Nemluvio® (nemolizumab) shows continued improvement in itch and skin lesions for up to two years in patients with Atopic Dermatitis by 2025. More Info: pryzm.ozmosi.com/product/6232 $XBI $IBB $XPH $PPH

HTL Biotechnology introduces a new production line for sterile hyaluronic acid. More Info: pryzm.ozmosi.com/product/19391 $XBI $IBB $XPH $PPH

Otsuka's Sibeprenlimab Phase 3 trial demonstrates significant proteinuria reduction in IgA Nephropathy treatment. More Info: pryzm.ozmosi.com/product/20777 $XBI $IBB $XPH $PPH

$BCRX BioCryst secures reimbursement for ORLADEYO in all major European countries. More Info: pryzm.ozmosi.com/product/16939 $XBI $IBB $XPH $PPH

$NRIX Nurix Therapeutics hosting webcast to review Phase 1 trial data for Bexobrutideg (NX-5948) at EHA2025 Congress. Join the call for updates. More Info: pryzm.ozmosi.com/product/24726 $XBI $IBB $XPH $PPH

$ARVN, PFE Arvinas submits new drug application to US FDA for Vepdegestrant in ESR1-mutated ER+/HER2advanced or metastatic breast cancer patients. More Info: pryzm.ozmosi.com/product/22165 $XBI $IBB $XPH $PPH

$OSTX OS Therapies has applied to the FDA for RMAT designation for OST-HER2 in preventing metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. More Info: pryzm.ozmosi.com/product/23166 $XBI $IBB $XPH $PPH

$AYTU Aytu BioPharma partners with Fabre-Kramer Pharmaceuticals to market EXXUA (gepirone) Extended-Release Tablets in the US, a unique antidepressant. More Info: pryzm.ozmosi.com/product/5006 $XBI $IBB $XPH $PPH

$APLS Apellis and Sobi reveal EMPAVELI® (pegcetacoplan) demonstrated lasting effectiveness after one year in Phase 3 trial for C3G and Primary IC-MPGN. More Info: pryzm.ozmosi.com/product/21862 $XBI $IBB $XPH $PPH

$SNGX Soligenix features Dr. Ellen Kim's recent Q&A and the potential of HyBryte™ in current clinical trials. More Info: pryzm.ozmosi.com/product/18781 $XBI $IBB $XPH $PPH

The European Commission has given approval for Duvyzat in treating Duchenne Muscular Dystrophy. More Info: pryzm.ozmosi.com/product/990 $XBI $IBB $XPH $PPH

$PHAT Phathom Pharmaceuticals gets FDA approval for 10-year exclusivity for vonoprazan tablets until May 3, 2032. More Info: pryzm.ozmosi.com/product/2388 $XBI $IBB $XPH $PPH

$REGN Dupixent® data presented at RAD Conference supports its effectiveness for atopic dermatitis patients with skin of color. More Info: pryzm.ozmosi.com/product/4253 $XBI $IBB $XPH $PPH